Evidence map›Paper›PMID 39209889›Full record

ArticleScientific reports2024

The epidemiology of lung cancer in Hungary based on the characteristics of patients diagnosed in 2018.

István Kenessey, Petra Parrag, Mária Dobozi, István Szatmári, András Wéber, Péter Nagy, Csaba Polgár

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

István Kenessey *National Institute of Oncology and National Tumor Biology Laboratory, Budapest, Hungary. kenessey.istvan@oncol.hu.
Petra Parrag *National Institute of Oncology and National Tumor Biology Laboratory, Budapest, Hungary.
Mária DoboziNational Institute of Oncology and National Tumor Biology Laboratory, Budapest, Hungary.
István SzatmáriNational Institute of Oncology and National Tumor Biology Laboratory, Budapest, Hungary.
András WéberNational Institute of Oncology and National Tumor Biology Laboratory, Budapest, Hungary.
Péter NagyNational Institute of Oncology and National Tumor Biology Laboratory, Budapest, Hungary.
Csaba PolgárNational Institute of Oncology and National Tumor Biology Laboratory, Budapest, Hungary.

Funding

National Research, Development and Innovation Fund of the Ministry of Culture and Innovation National Tumor Biology Laboratory (2022-2.1.1-NL-2022-00010World Health Organization 001
6 · The paper itself

Abstract

Among malignant diseases, lung cancer has one of the highest mortality and incidence. Most epidemiological studies conclude that Hungary faces the most severe burden in association with this disease. However, for various reasons estimates and population-based studies show discrepancies. In this study, an intense data cleansing was performed on lung cancer cases that were reported to the Hungarian National Cancer Registry in 2018, and the major clinico-pathological parameters as well as survival characteristics were described. Our population-based figures were compared to the European estimates. As a result of our thorough revision, the corrected incidence of lung cancer has fallen below the number of cases that were reported to the Registry from 11,746 to 9,519. We also demonstrate that Hungary did not show the highest incidence and mortality in Europe, but it is still among the ones with the worst raking countries, with 92.9 and 50.6 age standardized rate per 100 thousand capita among males and females, respectively. Analysis of the annually reported case numbers revealed a gender-specific difference in incidence trends: while from 2001 to 2019 it slightly decreased among males, it increased among females. The most dominant subtype was adenocarcinoma, which was more frequent among female patients. Unfortunately, most of the newly diagnosed cases were in advanced stage; thus, 5 year overall survival was 14.8%. We anticipate that in the longer term, a decrease in incidence and improvement in survival rates may be expected as a result of the development of primary and secondary prevention programs in the country.

Indexed as

Lung NeoplasmsRegistriesAdolescentAdultAgedAged, 80 and overFemaleHumansHungaryIncidenceMaleMiddle AgedYoung AdultCancer registryIncidenceInternational comparisonLung cancer in Hungary

Identifiers

PMID39209889
PMCPMC11362303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.